登录新浪财经APP 搜索【信披】查看更多考评等级 登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月19日晚间，卓然股份（维权）发布《关于公司及实际控制人收到立案告知书的公告》。公告 显示：上海卓然工程技术股份有限公司及实际控制人张锦红于2025年12月19日收到中国证券监督管理委 员会出具的《立案告知书》（证监立案字0032025031号、证监立案字0032025032号），因涉嫌信息披露 违法违规等事项，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会决定对公司及实际控制人张锦红立案。 在公告遭证监会立案的同时，卓然股份还发布了《关于收到上海证监局行政监管措施决定书的公告》， 经上海证监局调查，卓然股份存在以下违规：2021年至2024年期间 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 以上索赔条件仅代表陈宇霞律师的观点，不作为任何投资决策和买卖建议，最终以法院认定的索赔条件 为准。（陈宇霞律师专栏） 参加股票索赔的股民需准备一下材料； 1、股票交易对账单（如对账单上未显示完整的身份证号码，需另外打印股东信息表；对账期间从第一 次买入至完全卖出（或打印对账单之日） 2、身份证复印件 律师代理费 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月20日，上海卓然工程技术股份有限公司发布《关于公司及实际控制人收到立案告知书的公 告》，公告披露公司及实际控制人张锦红于2025年12月19日收到中国证券监督管理委员会（以下简 称"中国证监会"）出具的《立案告知书 》（ 证监立案字 0032025031号、证监立案字0032025032号）， 因涉嫌信息披露违法违规等事项，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法 律法规，中国证监会决定对公司及实际控制人 ...

Core Viewpoint - Jinhua Enterprises (Group) Co., Ltd. faces regulatory scrutiny due to its chairman's failure to disclose information related to his criminal investigation, resulting in a fine and warning from the Shaanxi Securities Regulatory Bureau [2] Company Summary - Jinhua Enterprises is a pharmaceutical industrial company engaged in the research, production, and sales of drugs, with a product line that includes chemical drugs, traditional Chinese medicine, raw materials, and health products [2] - The company reported a total operating revenue of 384 million yuan for the first three quarters, representing a year-on-year decline of 8.36% [2] - Net profit for the same period was 34.48 million yuan, showing a year-on-year increase of 12.06% [2] Regulatory Actions - Chairman Xing Yajiang received an administrative penalty decision from the Shaanxi Regulatory Bureau for failing to timely disclose information regarding his criminal investigation [2] - The penalty includes a warning and a fine of 3.5 million yuan [2] - A hearing was held on July 25, where Xing and his representatives presented their defense, which was ultimately not accepted upon review [2]

一、《行政处罚事先告知书》主要内容 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002424 证券简称：贵州百灵 公告编号：2025-053 贵州百灵企业集团制药股份有限公司 关于公司及相关当事人 收到《行政处罚事先告知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）于 2024 年11月8日收到中国证券监督管理委员 会（以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字0312024002号），因公司涉嫌 信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国 证监会决定对公司立案。具体内容详见公司于2024年11月9日在指定信息披露媒体《证券时报》《证券 日报》《中国证券报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn）披露的《关于收到中国证 券监督管理委员会〈立案告知书〉的公告》（公告编号：2024-067）。 2025 年 12月19日，公司及相关当事人分别收到中国证券监督管理委员会贵州监管局（以下简称"贵州 ...

Core Viewpoint - Jin Hua Enterprise (Group) Co., Ltd. faced regulatory penalties due to Chairman Xing Yajiang's failure to timely disclose personal legal matters, resulting in a warning and a fine of 3.5 million yuan from the Shaanxi Securities Regulatory Bureau [2][4]. Group 1: Regulatory Issues - Xing Yajiang was placed under residential surveillance by the Xi'an Public Security Bureau on April 23, 2024, but was released on July 26, 2024, due to insufficient evidence [4]. - The company disclosed the legal matter only on August 24, 2024, which was deemed a violation of information disclosure regulations by the Shaanxi Securities Regulatory Bureau [4]. - Xing's defense during the hearing, claiming uncertainty about his legal status and arguing that the punishment was excessive, was rejected due to lack of supporting evidence [4]. Group 2: Previous Violations - Since the beginning of 2024, Xing Yajiang has been involved in multiple regulatory violations, including inaccurate disclosures regarding Jin Hua's 2023 performance forecast, which led to criticism from the Shanghai Stock Exchange and a warning letter from the Shaanxi Securities Regulatory Bureau [5]. Group 3: Company Overview - Jin Hua's main business includes the research, production, and sales of pharmaceuticals, with a product line that encompasses chemical drugs, traditional Chinese medicine, raw materials, and health products [5]. - The company offers over a hundred varieties of dosage forms, including tablets, capsules, and granules, categorized into series such as orthopedic, immunological, pediatric, and general medicines [5].

Core Viewpoint - Fuyuan Dongfang has received a notice of administrative penalty for suspected violations of information disclosure laws, leading to a risk warning for its stock [2][3] Group 1: Company Announcements - On December 6, 2024, Fuyuan Dongfang received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations [2] - On December 19, 2025, the Guangdong Securities Regulatory Bureau issued a notice of administrative penalty to Fuyuan Dongfang [2] - The company reported that its subsidiary, Shenzhen Dayu Precision Technology Co., Ltd., inflated profits by 35,798,468.98 yuan in 2020, which accounted for 120.18% of the total profit disclosed in that year's annual report [2] Group 2: Financial Impact - In 2021, the company recognized a reduction in inflated prepayments, leading to a profit decrease of 22,650,928.29 yuan, which represented 6.64% of the total profit disclosed for that year [2] - The company has completed the sale of 100% equity in Dayu Precision in the first quarter of 2024, indicating that the subsidiary's business is unrelated to the company's current main operations [3] Group 3: Regulatory Actions - The Guangdong Securities Regulatory Bureau plans to impose a fine of 6.5 million yuan and issue a warning to Fuyuan Dongfang for the violations [3] - The stock will be subject to a risk warning, changing its name to "ST Fuyuan" while maintaining the stock code 300173, with a daily price fluctuation limit of 20% [3] Group 4: Company Response - The board of directors of Fuyuan Dongfang has issued an apology to investors and committed to reflecting on and rectifying past violations [4]

Core Viewpoint - Jiangsu Nuotai Aosaikeno Biopharmaceutical Co., Ltd. (ST Nuotai) has been penalized by the China Securities Regulatory Commission (CSRC) for falsifying financial statements, including inflating revenue by 30 million yuan and profit by 25.9516 million yuan, which accounted for 20.64% of the total profit disclosed for the period [1][8][11]. Summary by Sections Administrative Penalty - The CSRC issued an administrative penalty decision against ST Nuotai, ordering it to correct its actions, issuing a warning, and imposing a fine of 47.4 million yuan. Six responsible individuals were fined between 1.5 million and 13 million yuan, totaling 28.8 million yuan [1][20]. Violations Identified - ST Nuotai's 2021 annual report contained false records, specifically regarding a technology transfer to Zhejiang Huabei Pharmaceutical Co., Ltd., which lacked commercial substance and should not have been recognized as revenue. This transaction was linked to a capital increase from ST Nuotai to Zhejiang Huabei [8][11][12]. - The company’s public offering documents also contained significant false information, particularly in the financial accounting section, which misrepresented the 2021 financial data [10][11]. Responsible Individuals - Key individuals involved included Zhao Dezhong (Vice Chairman), Zhao Deyi (Chairman), Jin Fuqiang (General Manager), and others, who failed to ensure the accuracy of the financial reports and were found to have participated in the misleading transactions [9][12][17]. Company Response and Future Actions - ST Nuotai acknowledged the violations and expressed intentions to strengthen internal controls and compliance processes. The company aims to improve the quality of information disclosure and maintain the interests of shareholders [25][26].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600581 证券简称：八一钢铁（维权） 公告编号：临2025-075 新疆八一钢铁股份有限公司关于公司、控股股东及相关当事人 收到中国证券监督管理委员会新疆监管局《行政处罚事先告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 新疆八一钢铁股份有限公司（以下简称"八一钢铁"或"公司"）及控股股东新疆八一钢铁集团有限公司 （以下简称"八钢集团"）于2025年11月7日收到中国证券监督管理委员会（以下简称"中国证监会"）下 发的《立案告知书》。因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行 政处罚法》等法律法规，中国证监会决定对公司及八钢集团立案，具体情况详见公司于2025年11月8日 披露的《八一钢铁关于收到中国证券监督管理委员会立案告知书的公告》（公告编号：临2025-063）、 《八一钢铁关于中国证券监督管理委员会对控股股东立案调查的公告》（公告编号：临2025-064）。 2025年12月19日，公司、控股股东及相关当事人收到 ...

公司及实际控制人收到中国证监会出具的《立案告知书》。 12月19日，卓然股份(688121.SH)公告称，公司及实际控制人张锦红于2025年12月19日收到中国证监会 出具的《立案告知书》，因涉嫌信息披露违法违规等事项，中国证监会决定对公司及实际控制人张锦红 立案。目前公司各项经营活动和业务均正常开展。立案调查期间，公司及实际控制人将积极配合中国证 监会的相关工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 （文章来源：证券时报） 同日，公司收到上海证监局出具的《关于对上海卓然工程技术股份有限公司采取责令改正措施并对张锦 红、吴玉同、张笑毓采取出具警示函措施的决定》（沪证监决（ 2025 ）268 号）（以下简称《决定 书》）。 经查，公司存在以下违规事项: 2021年至2024年期间，公司在IPO募投项目实施过程中，违规支付部分募集资金，经由公司控股股东、 董事长张锦红有效控制的供应商或资金通道方银行账户流入体外资金池进行资金调配，部分资金在当日 或次日回流至公司非募集户，其余流向了张锦红间接控制的企业。公司未如实披露募集资金存放及实际 使用情况，亦未如实披露关联方非经营性资金往来情况。 公司上 ...

12月19日，卓然股份(688121)及实际控制人张锦红收到中国证监会出具的《立案告知书》，因涉嫌信息 披露违法违规等事项，中国证监会依法对卓然股份及实际控制人启动立案调查程序。公司于当日通过官 方公告作出回应，明确表示当前各项生产经营活动正常有序开展，业务运营未受实质性影响。在立案调 查期间，公司及实际控制人将全力配合监管机构的调查工作，严格遵循法律法规要求履行信息披露义 务，切实保障信息透明度与投资者知情权。 公司相关负责人表示，未来将始终坚守合规经营底线，持续完善内部控制体系，以更高标准规范运营管 理，确保公司治理水平不断提升。同时继续深化技术创新与绿色转型战略，聚焦核心业务拓展与新兴赛 道布局，通过提升技术壁垒与市场竞争力，实现经营业绩的稳健增长，以负责任的企业形象回馈投资者 与社会各界的信任。（厉平） ...